Federal Act
on Medicinal Products and Medical Devices
(Therapeutic Products Act, TPA)

¹ The Agency or the FO­CBS may or­der cov­ert sur­veil­lance meas­ures pur­su­ant to Art­icles 282 and 283 or 298a–298d Crim­PC²⁶⁰.

² Where a meas­ure un­der para­graph 1 lasts for more than 30 days, ap­prov­al is re­quired from the dir­ect­or of the or­der­ing au­thor­ity.

³ At the latest fol­low­ing con­clu­sion of the in­vest­ig­a­tion, the or­der­ing au­thor­ity shall no­ti­fy the per­son con­cerned of the reas­on, form and dur­a­tion of the cov­ert sur­veil­lance.

⁴ Where cov­ert sur­veil­lance meas­ures pur­su­ant to Art­icles 269–281 or 284–298 Crim­PC are con­sidered ne­ces­sary, the Agency or the FO­CBS shall no­ti­fy the Of­fice of the At­tor­ney Gen­er­al of Switzer­land (OAG) im­me­di­ately.

⁵ In cases un­der para­graph 4, the Agency or the FO­CBS with the agree­ment of the OAG shall ap­ply to the com­puls­ory meas­ures court. If the court ap­proves the meas­ures, the OAG shall take over the pro­ceed­ings in ac­cord­ance with the Crim­PC.